Search

Your search keyword '"Abrisqueta, Pau"' showing total 12 results
Start Over Author "Abrisqueta, Pau" Journal clinical lymphoma myeloma and leukemia
12 results on '"Abrisqueta, Pau"'

1. IBCL-474 Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

Author

Merryman, Reid W., primary, Belada, David, additional, Sureda, Anna, additional, Leppä, Sirpa, additional, Vermaat, Joost S.P., additional, Holte, Harald, additional, Hutchings, Martin, additional, Lugtenburg, Pieternella, additional, de Vos, Sven, additional, Abrisqueta, Pau, additional, Nijland, Marcel, additional, Christensen, Jacob Haaber, additional, Wahlin, Björn E., additional, Linton, Kim M., additional, Wang, Liwei, additional, Abbas, Aqeel, additional, Rana, Ali, additional, Quadri, Syed, additional, and Falchi, Lorenzo, additional

Published
2023
Full Text
View/download PDF

2. ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

Author

Duell, Johannes, primary, Abrisqueta, Pau, additional, Andre, Marc, additional, Augustin, Marinela, additional, Gaidano, Gianluca, additional, Barca, Eva González, additional, Jurczak, Wojciech, additional, Kalakonda, Nagesh, additional, Liberati, Anna Marina, additional, Maddocks, Kami J, additional, Menne, Tobias, additional, Nagy, Zsolt, additional, Tournilhac, Olivier, additional, Bakuli, Abhishek, additional, Amin, Aasim, additional, Gurbanov, Konstantin, additional, and Salles, Gilles, additional

Published
2023
Full Text
View/download PDF

3. POSTER: ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Author

Duell, Johannes, primary, Abrisqueta, Pau, additional, Dreyling, Martin, additional, Gaidano, Gianluca, additional, Barca, Eva González, additional, Jurczak, Wojciech, additional, Maddocks, Kami J, additional, Menne, Tobias, additional, Nagy, Zsolt, additional, Tournilhac, Olivier, additional, Bakuli, Abhishek, additional, Amin, Aasim, additional, Gurbanov, Konstantin, additional, and Salles, Gilles, additional

Published
2023
Full Text
View/download PDF

4. POSTER: ABCL-450 Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study

Author

Duell, Johannes, primary, Abrisqueta, Pau, additional, Andre, Marc, additional, Augustin, Marinela, additional, Gaidano, Gianluca, additional, Barca, Eva González, additional, Jurczak, Wojciech, additional, Kalakonda, Nagesh, additional, Liberati, Anna Marina, additional, Maddocks, Kami J, additional, Menne, Tobias, additional, Nagy, Zsolt, additional, Tournilhac, Olivier, additional, Bakuli, Abhishek, additional, Amin, Aasim, additional, Gurbanov, Konstantin, additional, and Salles, Gilles, additional

Published
2023
Full Text
View/download PDF

5. ABCL-482 Five-Year Subgroup Analysis of Tafasitamab + Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Author

Duell, Johannes, primary, Abrisqueta, Pau, additional, Dreyling, Martin, additional, Gaidano, Gianluca, additional, Barca, Eva González, additional, Jurczak, Wojciech, additional, Maddocks, Kami J, additional, Menne, Tobias, additional, Nagy, Zsolt, additional, Tournilhac, Olivier, additional, Bakuli, Abhishek, additional, Amin, Aasim, additional, Gurbanov, Konstantin, additional, and Salles, Gilles, additional

Published
2023
Full Text
View/download PDF

6. POSTER: IBCL-474 Epcoritamab + R2 Regimen and Responses in Patients With High-Risk Follicular Lymphoma, Regardless of POD24 Status

Author

Merryman, Reid W., primary, Belada, David, additional, Sureda, Anna, additional, Leppä, Sirpa, additional, Vermaat, Joost S.P., additional, Holte, Harald, additional, Hutchings, Martin, additional, Lugtenburg, Pieternella, additional, de Vos, Sven, additional, Abrisqueta, Pau, additional, Nijland, Marcel, additional, Christensen, Jacob Haaber, additional, Wahlin, Björn E., additional, Linton, Kim M., additional, Wang, Liwei, additional, Abbas, Aqeel, additional, Rana, Ali, additional, Quadri, Syed, additional, and Falchi, Lorenzo, additional

Published
2023
Full Text
View/download PDF

7. Poster: ABCL-388 L-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years

Author

Duell, Johannes, primary, Jurczak, Wojciech, additional, Liberati, Anna Marina, additional, Halka, Janusz, additional, Carbó, Esther Pena, additional, Abrisqueta, Pau, additional, Maddocks, Kami J, additional, Dreyling, Martin, additional, Rosenwald, Andreas, additional, Bakuli, Abhishek, additional, Amin, Aasim, additional, Gurbanov, Konstantin, additional, and Salles, Gilles, additional

Published
2022
Full Text
View/download PDF

8. ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

Author

Flowers, Christopher, primary, Tilly, Hervé, additional, Morschhauser, Franck, additional, Sehn, Laurie H., additional, Friedberg, Jonathan W., additional, Trněný, Marek, additional, Sharman, Jeff P., additional, Herbaux, Charles, additional, Burke, John M., additional, Matasar, Matthew, additional, Rai, Shinya, additional, Izutsu, Koji, additional, Mehta-Shah, Neha, additional, Oberic, Lucie, additional, Chauchet, Adrien, additional, Jurczak, Wojciech, additional, Song, Yuqin, additional, Greil, Richard, additional, Mykhalska, Larysa, additional, Bergua-Burgués, Juan Miguel, additional, Cheung, Matthew C., additional, Pinto, Antonio, additional, Shin, Ho-Jin, additional, Hapgood, Greg, additional, Munhoz, Eduardo, additional, Abrisqueta, Pau, additional, Gau, Jyh-Pyng, additional, Hirata, Jamie, additional, Jiang, Yanwen, additional, Yan, Mark, additional, Lee, Calvin, additional, and Salles, Gilles, additional

Published
2022
Full Text
View/download PDF

9. Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

Author

Flowers, Christopher, primary, Tilly, Hervé, additional, Morschhauser, Franck, additional, Sehn, Laurie H., additional, Friedberg, Jonathan W., additional, Trněný, Marek, additional, Sharman, Jeff P., additional, Herbaux, Charles, additional, Burke, John M., additional, Matasar, Matthew, additional, Rai, Shinya, additional, Izutsu, Koji, additional, Mehta-Shah, Neha, additional, Oberic, Lucie, additional, Chauchet, Adrien, additional, Jurczak, Wojciech, additional, Song, Yuqin, additional, Greil, Richard, additional, Mykhalska, Larysa, additional, Bergua-Burgués, Juan Miguel, additional, Cheung, Matthew C., additional, Pinto, Antonio, additional, Shin, Ho-Jin, additional, Hapgood, Greg, additional, Munhoz, Eduardo, additional, Abrisqueta, Pau, additional, Gau, Jyh-Pyng, additional, Hirata, Jamie, additional, Jiang, Yanwen, additional, Yan, Mark, additional, Lee, Calvin, additional, and Salles, Gilles, additional

Published
2022
Full Text
View/download PDF

10. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

Author

Abrisqueta, Pau, primary, Loscertales, Javier, additional, Terol, Maria José, additional, Ramírez Payer, Ángel, additional, Ortiz, Macarena, additional, Pérez, Inmaculada, additional, Cuellar-García, Carolina, additional, Fernández de la Mata, Margarita, additional, Rodríguez, Alicia, additional, Lario, Ana, additional, Delgado, Julio, additional, Godoy, Ana, additional, Arguiñano Pérez, José Mª, additional, Berruezo, Mª José, additional, Oliveira, Ana, additional, Hernández-Rivas, José-Ángel, additional, García Malo, Maria Dolores, additional, Medina, Ángeles, additional, García Martin, Paloma, additional, Osorio, Santiago, additional, Baltasar, Patricia, additional, Fernández-Zarzoso, Miguel, additional, Marco, Fernando, additional, Vidal Manceñido, Mª Jesús, additional, Smucler Simonovich, Alicia, additional, López Rubio, Montserrat, additional, Jarque, Isidro, additional, Suarez, Alexia, additional, Fernández Álvarez, Rubén, additional, Lancharro Anchel, Aima, additional, Ríos, Eduardo, additional, Losada Castillo, María del Carmen, additional, Pérez Persona, Ernesto, additional, García Muñoz, Ricardo, additional, Ramos, Rafael, additional, Yáñez, Lucrecia, additional, Bello, José Luis, additional, Loriente, Cristina, additional, Acha, Daniel, additional, and Villanueva, Miguel, additional

Published
2021
Full Text
View/download PDF

11. ABCL-170: Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (MOR208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Author

Salles, Gilles, primary, Duell, Johannes, additional, González-Barca, Eva, additional, Jurczak, Wojciech, additional, Marina Liberati, Anna, additional, de Vos, Sven, additional, Nagy, Zsolt, additional, Obr, Aleš, additional, Gaidano, Gianluca, additional, Abrisqueta, Pau, additional, Kalakonda, Nagesh, additional, André, Marc, additional, Dreyling, Martin, additional, Menne, Tobias, additional, Tournilhac, Olivier, additional, Augustin, Marinela, additional, Dirnberger-Hertweck, Maren, additional, Weirather, Johannes, additional, Ambarkhane, Sumeet, additional, and Maddocks, Kami J, additional

Published
2020
Full Text
View/download PDF

12. 5.40 Rituximab Maintenance in Patients with Chronic Lymphocytic Leukemia after First-Line Treatment with Rituximab plus Fludarabine, Cyclophosphamide, and Mitoxantrone: Final Results of a Multicenter Phase II Trial on Behalf of the Spanish CLL Study Group (GELLC)

Author

Bosch, Francesc, Abrisqueta, Pau, Villamor, Neus, Terol, María José, González-Barca, Eva, González, Marcos, Ferrà, Christelle, Abella, Eugenia, Delgado, Julio, Garcia-Marco, Jose A., Gonzalez, Yolanda, Carbonell, Felix, Ferrer, Secundino, Monzo, Encarna, Jarque, Isidro, Muntanola, Ana, Constants, Mireia, Escoda, Lourdes, and Montserrat, Emili

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results